This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Trius Therapeutics Reports Data On Broad-Spectrum Antibiotics At 52nd Annual ICAAC Meeting

SAN FRANCISCO, Sept. 12, 2012 (GLOBE NEWSWIRE) -- ICAAC 2012 -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections, today announced preclinical studies related to a new class of broad-spectrum, gram-negative antibacterial agents that are directed against novel targets Gyrase B (GyrB) and ParE. Trius scientists and research collaborators are presenting the results at the 52 nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting being held in San Francisco from September 9-12, 2012. Fourteen posters and one podium presentation related to the company's GyrB/ParE preclinical program are being featured, including both in vivo and in vitro studies.

Currently there are no antibiotics in clinical use that inhibit both GyrB and ParE—two microbial enzymes essential for the replication of bacteria. As a result of the crisis of increasing bacterial resistance, there is an urgent need for new antibiotics, especially those active against common clinical infections caused by gram-negative pathogens. However, the development pipeline of gram-negative agents to replace resistant therapies is limited. Treatment of gram-negative bacterial infections can be difficult, because of the pathogen's double cell membrane, efflux pumps and ability to quickly mutate to develop resistance. As of 2011, the Centers for Disease Control and Prevention estimates that roughly 1.7 million hospital-associated infections, from all types of bacteria, cause or contribute to 99,000 deaths each year.

The data abstracts examine the effect of Trius' antibacterial agents against a panel of gram-positive and gram-negative pathogens. The results show significant potency in treating challenging gram-negative bacteria associated with hospital-acquired infections, such as Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumonias, and biodefense pathogens such as Yersinia pestis (plague), Francisella tularensis, Burkholderia mallei and Burkholderia pseudomallei.

As reported in the presentations, Trius' antibacterial agents exhibit bactericidal (bacteria-killing) activity, low minimum inhibitory concentrations (MICs), and reduced emergence of bacterial resistance versus comparators such as ciprofloxacin. The compounds' dual-targeting mechanism may impair bacteria's ability to develop resistance, as suggested by previous studies. 1,2 These dual-inhibitor agents also avoid cross-resistance with established antibiotic classes, including the fluoroquinolones. This is consistent with the fact that the compounds bind to different subunits of DNA gyrase and topoisomerase IV than current antibiotics, such as fluoroquinolones. 

"The preclinical studies demonstrate potent activity against gram-negative pathogens, supporting the continued development of broad-spectrum antibiotics targeting GyrB and ParE," said Jeff Stein, President and Chief Executive Officer at Trius Therapeutics. "Since the discovery of quinolones in the 1960s, we believe this is the first new chemical class of antibiotics with potent activity against a wide range of gram-positive and gram-negative bacteria. The emergence of multi-drug resistant infections underscores the need for unique antibacterial agents. Based on the encouraging results, we look forward to submitting an Investigational New Drug (IND) application and anticipate initiating a Phase 1 trial in 2013."

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,919.59 +80.85 0.48%
S&P 500 1,981.60 +9.86 0.50%
NASDAQ 4,527.5140 +19.2020 0.43%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs